Financhill
Back

Ocular Therapeutix Quote, Financials, Valuation and Earnings

Buy
72

OCUL
Ocular Therapeutix

Last Price:
6.29
Seasonality Move:
-2.15%

7 Day Trial

ALL ACCESS PASS

$ 7

Ocular Therapeutix Price Quote

$6.29

Ocular Therapeutix Key Stats

Buy
72
Ocular Therapeutix (OCUL) is a Buy

Day range:
$6.23 - $6.60
52-week range:
$2.00 - $11.31
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
10.13
P/B ratio:
2.39%

Volume:
3.7M
Avg. volume:
2.9M
1-year change:
-0.63%
Market cap:
$974.3M
Revenue:
$58.4M
EPS:
$-1.35

How Much Does Ocular Therapeutix Make?

Is Ocular Therapeutix Growing As A Company?

  • What Is Ocular Therapeutix's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.1%
  • What Is Ocular Therapeutix's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Ocular Therapeutix Stock Price Performance

What Is Ocular Therapeutix 52-Week High & Low?

Ocular Therapeutix Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Ocular Therapeutix?

  • How Much Debt Does Ocular Therapeutix Have?
    Total long term debt quarterly is $66.5M
  • How Much Cash Does Ocular Therapeutix Have?
    Cash and short term investments quarterly total is $482.9M
  • What Is Ocular Therapeutix’s Book Value Per Share?
    Book value per share is 2.64

Is Ocular Therapeutix Cash Flow Positive?

  • What Is OCUL Cash Flow From Operations?
    Cash flow from operations (TTM) is -$84.1M
  • What Is Ocular Therapeutix’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $491M
  • What Is Ocular Therapeutix’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$3M

Ocular Therapeutix Return On Invested Capital

  • Is Management Doing A Good Job?
    OCUL return on invested capital is -68.2%
  • What Is Ocular Therapeutix Return On Assets?
    ROA measures how assets are converting to revenues and is -47.85%
  • What Is OCUL Return On Equity?
    ROE is a measure of profitability and is -110.88%

Ocular Therapeutix Earnings Date & Stock Price

Ocular Therapeutix Competitors

Ocular Therapeutix Dividend Yield

Data Unavailable

Ocular Therapeutix Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -33.33%
Revenue: 10.47% -3.82%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 14.50
Upside from Last Price: 130.52%

Major Shareholders

  • How many OCUL shares are owned by institutional investors?
    95.8M OCUL shares are owned by institutional investors
  • How many OCUL shares are owned by insiders?
    4.2M OCUL shares are owned by insiders